Disruption of prostate epithelial differentiation pathways and prostate cancer development

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Frank, Sander B ^a,b   Miranti, Cindy K ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Differentiation; Myc; Notch; P38MAPK; Prostate cancer; Pten

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 10; FOCAL ADHESION KINASE; INTEGRIN; INTERLEUKIN 6; KERATIN; KERATINOCYTE GROWTH FACTOR; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR ETS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POLARITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME DELETION; DNA DAMAGE; DOWN REGULATION; DUSP1 GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE; GENE DELETION; GENE OVEREXPRESSION; HUMAN; IMMUNOBLOTTING; LUNG SQUAMOUS CELL CARCINOMA; NONHUMAN; ONCOGENE C MYC; PROSTATE CANCER; PROTEIN EXPRESSION; STEM CELL; TUMOR GROWTH; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84891046643     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00273     Document Type: Article

References (318)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63(1):11-30. doi: 10.3322/caac.21166
2. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 98(5):355-7. doi:10.1093/jnci/djj072
3. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, et al. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. Cancer (2012) 118(10):2651-8. doi:10.1002/cncr.26396
4. Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol (2004) 172(5 Pt 2):S48-50. doi:10.1097/01.ju.0000141712.79986.77
5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 18(1):11-22. doi:10.1016/j.ccr.2010.05.026
6. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene (2007) 26(15):2226-42. doi:10.1038/sj.onc.1210291
7. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 7(4):295-308. doi:10.1038/nrc2175
8. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339(6127):1546-58. doi:10.1126/science.1235122
9. Cunha GR. Mesenchymal-epithelial interactions: past, present, and future. Differentiation (2008) 76(6):578-86. doi:10.1111/j.1432-0436.2008.00290.x
10. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The a6ß1 and a6ß4 integrins in human prostate cancer progression. Cancer Metastasis Rev (1995) 14(3):219-28. doi:10.1007/BF00690293
11. Lamb LE, Zarif JC, Miranti CK. The androgen receptor induces integrin alpha6beta1 to promote prostate tumor cell survival via NF-kappaB and Bcl-xL Independently of PI3K signaling. Cancer Res (2011) 71(7):2739-49. doi:10.1158/0008-5472.CAN-10-2745
12. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology (2003) 62(5 Suppl 1):11-20. doi:10.1016/S0090-4295(03)00758-1
13. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 52(22):6182-7.
14. Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 15(3):274-83. doi:10.1038/ncb2697
15. de Muga S, Hernandez S, Agell L, Salido M, Juanpere N, Lorenzo M, et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod Pathol (2010) 23(5):703-12. doi:10.1038/modpathol.2010.45
16. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, et al. Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer (2011) 11:31. doi:10.1186/1471-2407-11-31
17. Lamb LE, Knudsen BS, Miranti CK. E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J Cell Sci (2010) 123(Pt 2):266-76. doi:10.1242/jcs.054502
18. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate (2002) 51(2):98-107. doi:10.1002/pros.10073
19. Carvalho JR, Filipe L, Costa VL, Ribeiro FR, Martins AT, Teixeira MR, et al. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis (2010) 15(8):956-65. doi:10.1007/s10495-010-0508-6
20. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res (1992) 52(24):6940-4.
21. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 11(3):229-42. doi:10.1002/pros.2990110304
22. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2:33-50. doi:10.1002/pros.2990150506
23. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 153(3):911-9. doi:10.1016/S0002-9440(10)65632-5
24. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation (2005) 73(9-10):463-73. doi:10.1111/j.1432-0436.2005.00047.x
25. Ousset M, Van Keymeulen A, Bouvencourt G, Sharma N, Achouri Y, Simons BD, et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol (2012) 14(11):1131-8. doi:10.1038/ncb2600
26. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature (2009) 461(7263):495-500. doi:10.1038/nature08361
27. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature (2008) 456(7223):804-8. doi:10.1038/nature07427
28. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, et al. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate (2010) 70(5):491-501. doi:10.1002/pros.21083
29. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A (2007) 104(1):181-6. doi:10.1073/pnas.0609684104
30. Xin L, Ide H, Kim Y, Dubey P, Witte ON. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 1:11896-903. doi:10.1073/pnas.1734139100
31. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A (2005) 102(19):6942-7. doi:10.1073/pnas.0502320102
32. Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 34(4):292-301. doi:10.1002/(SICI)1097-0045(19980301)34:4<292::AID-PROS7>3.0.CO;2-J
33. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science (2010) 329(5991):568-71. doi:10.1126/science.1189992
34. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A (2010) 107(6):2610-5. doi:10.1073/pnas.0913873107
35. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 103(5):1480-5. doi:10.1073/pnas.0510652103
36. Choi N, Zhang B, Zhang L, Ittmann M, Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 21(2):253-65. doi:10.1016/j.ccr.2012.01.005
37. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, et al. The current state of preclinical prostate cancer animal models. Prostate (2008) 68(6):629-39. doi:10.1002/pros.20726
38. Valkenburg KC, Williams BO. Mouse models of prostate cancer. Prostate Cancer (2011) 2011:895238. doi:10.1155/2011/895238
39. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet (2002) 18(5):S1-5. doi:10.1016/S0168-9525(02)02683-5
40. McNeal JE. The zonal anatomy of the prostate. Prostate (1981) 2(1):35-49. doi:10.1002/pros.2990020105
41. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, et al. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation (1998) 63(3):131-40. doi:10.1046/j.1432-0436.1998.6330131.x
42. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, et al. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc (2011) 6(5):656-67. doi:10.1038/nprot.2011.317
43. Heer R, Collins AT, Robson CN, Shenton BK, Leung HY. KGF suppresses a2ß1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium. J Cell Sci (2006) 119(Pt 7):1416-24. doi:10.1242/jcs.02802
44. Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate (1993) 23(1):69-78. doi:10.1002/pros.2990230107
45. van Leenders GJ, Schalken JA. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol (2003) 27(46):S3-10. doi:10.1016/S1040-8428(03)00059-3
46. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol (2012) 24(3):251-7. doi:10.1097/CCO.0b013e32835105b3
47. Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Curr Opin Urol (2012) 22(3):167-74. doi:10.1097/MOU.0b013e3283523b8b
48. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol (2012) 360(1-2):38-43. doi:10.1016/j.mce.2011.12.019
49. da Silva HB, Amaral EP, Nolasco EL, de Victo NC, Atique R, Jank CC, et al. Dissecting major signaling pathways throughout the development of prostate cancer. Prostate Cancer (2013) 920612(10):29. doi:10.1155/2013/920612
50. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 15(6):319-31. doi:10.1097/PAP.0b013e31818a5c19
51. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer (2010) 1(6):617-28. doi:10.1177/1947601910379132
52. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 4(3):223-38. doi:10.1016/S1535-6108(03)00197-1
53. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 67(18):8504-10. doi:10.1158/0008-5472.CAN-07-0673
54. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 153(1):141-8. doi:10.1016/S0002-9440(10)65554-X
55. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 21(9):1156-67. doi:10.1038/modpathol.2008.111
56. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res (2003) 9(14):5271-81.
57. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 78(10):1296-300. doi:10.1038/bjc.1998.674
58. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 13(5):283-96. doi:10.1038/nrm3330
59. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 44(6):685-9. doi:10.1038/ng.2279
60. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 17(20):6563-73. doi:10.1158/1078-0432.CCR-11-1244
61. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 208(5):699-707. doi:10.1002/path.1929
62. Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2013) 26(3):435-47. doi:10.1038/modpathol.2012.162
63. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A (2001) 98(20):11563-8. doi:10.1073/pnas.201167798
64. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 1(3):27. doi:10.1371/journal.pbio.0000059
65. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 65(13):5730-9. doi:10.1158/0008-5472.CAN-04-4519
66. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 4(3):209-21. doi:10.1016/S1535-6108(03)00215-0
67. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer (2007) 97(5):678-85. doi:10.1038/sj.bjc.6603924
68. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 169(2):128-37. doi:10.1016/j.cancergencyto.2006.04.003
69. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 6(8):429-39. doi:10.1038/nrurol.2009.127
70. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 56(2):275-86. doi:10.1016/j.eururo.2009.04.036
71. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 26(31):4596-9. doi:10.1038/sj.onc.1210237
72. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310(5748):644-8. doi:10.1126/science.1117679
73. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol (2008) 21(2):67-75. doi:10.1038/modpathol.3800981
74. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 31(6):882-8. doi:10.1097/01.pas.0000213424.38503.aa
75. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 10(2):177-88. doi:10.1593/neo.07822
76. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 17(5):443-54. doi:10.1016/j.ccr.2010.03.018
77. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 27(40):5348-53. doi:10.1038/onc.2008.183
78. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 68(20):8516-24. doi:10.1158/0008-5472.CAN-08-1147
79. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 8(7):497-511. doi:10.1038/nrc2402
80. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 16(7):793-8. doi:10.1038/nm.2166
81. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol (2004) 92(4):221-36. doi:10.1016/j.jsbmb.2004.10.017
82. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 104(31):12679-84. doi:10.1073/pnas.0704940104
83. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 64(24):8867-75. doi:10.1158/0008-5472.CAN-04-2938
84. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ (2002) 13(1):1-11.
85. Shaikhibrahim Z, Wernert N. ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review). Int J Oncol (2012) 40(6):1748-54. doi:10.3892/ijo.2012.1380
86. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 19(8):1023-9. doi:10.1038/nm.3216
87. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 41(5):619-24. doi:10.1038/ng.370
88. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 41(5):524-6. doi:10.1038/ng.371
89. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 105(6):2105-10. doi:10.1073/pnas.0711711105
90. Gandarillas A. The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint. Cell Cycle (2012) 11(24):4507-16. doi:10.4161/cc.22529
91. Watt FM, Frye M, Benitah SA. MYC in mammalian epidermis: how can an oncogene stimulate differentiation? Nat Rev Cancer (2008) 8(3):234-42. doi:10.1038/nrc2328
92. Cascon A, Robledo M. MAX and MYC: a heritable breakup. Cancer Res (2012) 72(13):3119-24. doi:10.1158/0008-5472.CAN-11-3891
93. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell (2010) 141(3):432-45. doi:10.1016/j.cell.2010.03.030
94. Varlakhanova NV, Knoepfler PS. Acting locally and globally: Myc's ever-expanding roles on chromatin. Cancer Res (2009) 69(19):7487-90. doi:10.1158/0008-5472.CAN-08-4832
95. Luscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene (2012) 494(2):145-60. doi:10.1016/j.gene.2011.12.027
96. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. EMBO J (1997) 16(18):5672-86. doi:10.1093/emboj/16.18.5672
97. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2008) 40(1):43-50. doi:10.1038/ng.2007.30
98. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 12(3):247-56. doi:10.1038/ncb2024
99. Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res (2011) 110:77-106. doi:10.1016/B978-0-12-386469-7.00004-9
100. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem (2006) 281(46):34725-9. doi:10.1074/jbc.R600017200
101. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell (2004) 116(4):499-509. doi:10.1016/S0092-8674(04)00127-8
102. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 100(14):8164-9. doi:10.1073/pnas.1332764100
103. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate (1987) 11(4):327-37. doi:10.1002/pros.2990110405
104. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res (1986) 46(3):1535-8.
105. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 41(10):1058-60. doi:10.1038/ng.452
106. Porkka KP, Tammela TL, Vessella RL, Visakorpi T. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer (2004) 39(1):1-10. doi:10.1002/gcc.10289
107. Tsuchiya N, Kondo Y, Takahashi A, Pawar H, Qian J, Sato K, et al. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol (2002) 160(5):1799-806. doi:10.1016/S0002-9440(10)61126-1
108. Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 10(8):897-907.
109. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 112(11):1724-31. doi:10.1172/JCI200319035
110. Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 8(5):e63563. doi:10.1371/journal.pone.0063563
111. Grad JM, Dai JL, Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol (1999) 13(11):1896-911. doi:10.1210/me.13.11.1896
112. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem (2012) 287(2):1527-37. doi:10.1074/jbc.M111.278705
113. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, et al. Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate (2009) 69(3):249-62. doi:10.1002/pros.20877
114. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol (2004) 202(2):233-40. doi:10.1002/path.1503
115. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 64(6):1975-86. doi:10.1158/0008-5472.CAN-03-3972
116. Zhu H, Zhou X, Redfield S, Lewin J, Miele L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res (2013) 5(3):368-78.
117. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res (2009) 15(2):452-9. doi:10.1158/1078-0432.CCR-08-1631
118. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate (2000) 43(4):278-85. doi:10.1002/1097-0045(20000601)43:4<278::AID-PROS7>3.0.CO;2-4
119. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 393(6684):483-7. doi:10.1038/31008
120. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev (2008) 22(20):2755-66. doi:10.1101/gad.1712408
121. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663-76. doi:10.1016/j.cell.2006.07.024
122. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F, et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A (2010) 107(20):9222-7. doi:10.1073/pnas.1004584107
123. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2008) 26(1):101-6. doi:10.1038/nbt1374
124. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development (2005) 132(5):885-96. doi:10.1242/dev.01670
125. Varlakhanova NV, Cotterman RF, deVries WN, Morgan J, Donahue LR, Murray S, et al. Myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation (2010) 80(1):9-19. doi:10.1016/j.diff.2010.05.001
126. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A (2001) 98(7):3826-31. doi:10.1073/pnas.071043198
127. Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev (2001) 15(16):2042-7. doi:10.1101/gad.907901
128. Sumi T, Tsuneyoshi N, Nakatsuji N, Suemori H. Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc. Oncogene (2007) 26(38):5564-76. doi:10.1038/sj.onc.1210353
129. Bull JJ, Muller-Rover S, Patel SV, Chronnell CM, McKay IA, Philpott MP. Contrasting localization of c-Myc with other Myc superfamily transcription factors in the human hair follicle and during the hair growth cycle. J Invest Dermatol (2001) 116(4):617-22. doi:10.1046/j.1523-1747.2001.12771234.x
130. Gandarillas A, Watt FM. Changes in expression of members of the fos and jun families and myc network during terminal differentiation of human keratinocytes. Oncogene (1995) 11(7):1403-7.
131. Gandarillas A, Watt FM. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev (1997) 11(21):2869-82. doi:10.1101/gad.11.21.2869
132. Gebhardt A, Frye M, Herold S, Benitah SA, Braun K, Samans B, et al. Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1. J Cell Biol (2006) 172(1):139-49. doi:10.1083/jcb.200506057
133. Hashiro M, Matsumoto K, Okumura H, Hashimoto K, Yoshikawa K. Growth inhibition of human keratinocytes by antisense c-myc oligomer is not coupled to induction of differentiation. Biochem Biophys Res Commun (1991) 174(1):287-92. doi:10.1016/0006-291X(91)90518-C
134. Watt FM. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J (2002) 21(15):3919-26. doi:10.1093/emboj/cdf399
135. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol (2000) 20(2):556-62. doi:10.1128/MCB.20.2.556-562.2000
136. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, et al. Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol (2012) 181(2):560-9. doi:10.1016/j.ajpath.2012.04.021
137. Efroni S, Duttagupta R, Cheng J, Dehghani H, Hoeppner DJ, Dash C, et al. Global transcription in pluripotent embryonic stem cells. Cell Stem Cell (2008) 2(5):437-47. doi:10.1016/j.stem.2008.03.021
138. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 2(9):669-83.
139. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 338(6113):1465-9. doi:10.1126/science.1227604
140. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem (2006) 97(3):433-47. doi:10.1002/jcb.20696
141. Frye M, Gardner C, Li ER, Arnold I, Watt FM. Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. Development (2003) 130(12):2793-808. doi:10.1242/dev.00462
142. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J (2010) 429(3):403-17. doi:10.1042/BJ20100323
143. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9(8):537-49. doi:10.1038/nrc2694
144. Belleudi F, Purpura V, Torrisi MR. The receptor tyrosine kinase FGFR2b/KGFR controls early differentiation of human keratinocytes. PLoS One (2011) 6(9):21. doi:10.1371/journal.pone.0024194
145. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 10(2):116-29. doi:10.1038/nrc2780
146. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev (2008) 27(2):253-61. doi:10.1007/s10555-008-9123-1
147. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate (2003) 55(2):128-39. doi:10.1002/pros.10212
148. Rajashekhar G, Kamocka M, Marin A, Suckow MA, Wolter WR, Badve S, et al. Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J Cell Physiol (2011) 226(3):800-8. doi:10.1002/jcp.22404
149. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol (2002) 33(3):299-306. doi:10.1053/hupa.2002.32227
150. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, et al. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol (2007) 212(4):386-94. doi:10.1002/path.2194
151. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol (2006) 208(3):401-7. doi:10.1002/path.1910
152. Ricote M, Garcia-Tunon I, Fraile B, Fernandez C, Aller P, Paniagua R, et al. P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis (2006) 11(11):1969-75. doi:10.1007/s10495-006-0086-9
153. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol (1996) 149(5):1553-64.
154. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL, Visakorpi T. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer (2005) 117(5):738-45. doi:10.1002/ijc.21270
155. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest (1997) 76(1):37-51.
156. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch (1998) 432(5):407-13. doi:10.1007/s004280050184
157. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, et al. Gene expression pathways of high grade localized prostate cancer. Prostate (2011) 25(10):21373. doi:10.1002/pros.21373
158. Manetsch M, Che W, Seidel P, Chen Y, Ammit AJ. MKP-1: a negative feedback effector that represses MAPK-mediated pro-inflammatory signaling pathways and cytokine secretion in human airway smooth muscle cells. Cell Signal (2012) 24(4):907-13. doi:10.1016/j.cellsig.2011.12.013
159. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2002) 277(9):7076-85. doi:10.1074/jbc.M108255200
160. Zauberman A, Zipori D, Krupsky M, Ben-Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene (1999) 18(26):3886-93. doi:10.1038/sj.onc.1202738
161. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2012) 360(1-2):52-8. doi:10.1016/j.mce.2011.05.033
162. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res (2001) 7(6):1773-81.
163. Gan L, Wang J, Xu H, Yang X. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate (2011) 71(11):1158-66. doi:10.1002/pros.21331
164. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate (2013) 73(4):418-27. doi:10.1002/pros.22583
165. Frey MR, Golovin A, Polk DB. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J Biol Chem (2004) 279(43):44513-21. doi:10.1074/jbc.M406253200
166. Lewis DA, Spandau DF. UVB-induced activation of NF-?B is regulated by the IGF-1R and dependent on p38 MAPK. J Invest Dermatol (2008) 128(4):1022-9. doi:10.1038/sj.jid.5701127
167. McCawley LJ, Li S, Wattenberg EV, Hudson LG. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem (1999) 274(7):4347-53. doi:10.1074/jbc.274.7.4347
168. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer (2004) 11(4):709-24. doi:10.1677/erc.1.00535
169. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 12(6):572-85. doi:10.1016/j.ccr.2007.11.002
170. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 12(6):559-71. doi:10.1016/j.ccr.2007.11.004
171. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate (2001) 46(2):163-72. doi:10.1002/1097-0045(20010201)46:2<163::AID-PROS1020>3.0.CO;2-T
172. Houde M, Laprise P, Jean D, Blais M, Asselin C, Rivard N. Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2. J Biol Chem (2001) 276(24):21885-94. doi:10.1074/jbc.M100236200
173. Sharma GD, He J, Bazan HE. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem (2003) 278(24):21989-97. doi:10.1074/jbc.M302650200
174. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38a MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 39(6):750-8. doi:10.1038/ng2037
175. Wang X, Goh CH, Li B. p38 Mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology (2007) 148(4):1629-37. doi:10.1210/en.2006-1000
176. Dashti SR, Efimova T, Eckert RL. MEK6 regulates human involucrin gene expression via a p38a-and p38d-dependent mechanism. J Biol Chem (2001) 276(29):27214-20. doi:10.1074/jbc.M100465200
177. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38a results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med (2000) 191(5):859-70. doi:10.1084/jem.191.5.859
178. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 24(6):1134-45. doi:10.1038/sj.emboj.7600578
179. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, et al. p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res (2009) 69(11):4648-55. doi:10.1158/0008-5472.CAN-08-4455
180. Efimova T, Broome AM, Eckert RL. A regulatory role for p38d MAPK in keratinocyte differentiation. Evidence for p38d-ERK1/2 complex formation. J Biol Chem (2003) 278(36):34277-85. doi:10.1074/jbc.M302759200
181. Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol Cell Endocrinol (2006) 252(1-2):224-30. doi:10.1016/j.mce.2006.03.017
182. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 19(10):1175-87. doi:10.1101/gad.1306705
183. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha Suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 39(6):741-9. doi:10.1038/ng2033
184. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 14(5):574-84. doi:10.1101/gad.14.5.574
185. Hall JP, Davis RJ. Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line. J Cell Biochem (2002) 86(1):1-11. doi:10.1002/jcb.10187
186. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol (1999) 27(1):64-71. doi:10.1177/019262339902700113
187. Mehta PB, Robson CN, Neal DE, Leung HY. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene (2001) 20(38):5359-65. doi:10.1038/sj.onc.1204688
188. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A (1992) 89(1):246-50. doi:10.1073/pnas.89.1.246
189. Donjacour AA, Thomson AA, Cunha GR. FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol (2003) 261(1):39-54. doi:10.1016/S0012-1606(03)00250-1
190. Lin Y, Liu G, Zhang Y, Hu YP, Yu K, Lin C, et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development (2007) 134(4):723-34. doi:10.1242/dev.02765
191. Leong KG, Gao WQ. The notch pathway in prostate development and cancer. Differentiation (2008) 76(6):699-716. doi:10.1111/j.1432-0436.2008.00288.x
192. Kopan R, Ilagan MX. The canonical notch signaling pathway: unfolding the activation mechanism. Cell (2009) 137(2):216-33. doi:10.1016/j.cell.2009.03.045
193. Wang MM. Notch signaling and notch signaling modifiers. Int J Biochem Cell Biol (2011) 43(11):1550-62. doi:10.1016/j.biocel.2011.08.005
194. Fischer A, Gessler M. Delta-notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res (2007) 35(14):4583-96. doi:10.1093/nar/gkm477
195. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 20(15):2096-109. doi:10.1101/gad.1450406
196. Shimizu K, Chiba S, Saito T, Kumano K, Hamada Y, Hirai H. Functional diversity among Notch1, Notch2, and Notch3 receptors. Biochem Biophys Res Commun (2002) 291(4):775-9. doi:10.1006/bbrc.2002.6528
197. Yuan Z, Friedmann DR, VanderWielen BD, Collins KJ, Kovall RA. Characterization of CSL (CBF-1, Su(H), Lag-1) mutants reveals differences in signaling mediated by Notch1 and Notch2. J Biol Chem (2012) 287(42):34904-16. doi:10.1074/jbc.M112.403287
198. Barolo S, Walker RG, Polyanovsky AD, Freschi G, Keil T, Posakony JW. A notch-independent activity of suppressor of hairless is required for normal mechanoreceptor physiology. Cell (2000) 103(6):957-69. doi:10.1016/S0092-8674(00)00198-7
199. Martinez Arias A, Zecchini V, Brennan K. CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr Opin Genet Dev (2002) 12(5):524-33. doi:10.1016/S0959-437X(02)00336-2
200. Johnson JE, Macdonald RJ. Notch-independent functions of CSL. Curr Top Dev Biol (2011) 97:55-74. doi:10.1016/B978-0-12-385975-4.00009-7
201. Minter LM, Osborne BA. Canonical and non-canonical notch signaling in CD4(+) T cells. Curr Top Microbiol Immunol (2012) 360:99-114. doi:10.1007/82_2012_233
202. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell (2009) 16(5):633-47. doi:10.1016/j.devcel.2009.03.010
203. Roy M, Pear WS, Aster JC. The multifaceted role of notch in cancer. Curr Opin Genet Dev (2007) 17(1):52-9. doi:10.1016/j.gde.2006.12.001
204. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 67(5):1879-82. doi:10.1158/0008-5472.CAN-06-3958
205. Tzoneva G, Ferrando AA. Recent advances on NOTCH signaling in T-ALL. Curr Top Microbiol Immunol (2012) 360:163-82. doi:10.1007/82_2012_232
206. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 122(10):3398-406. doi:10.1172/JCI61269
207. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269-71. doi:10.1126/science.1102160
208. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 108(43):17761-6. doi:10.1073/pnas.1114669108
209. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell (2009) 16(1):55-66. doi:10.1016/j.ccr.2009.05.016
210. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 11(5):338-51. doi:10.1038/nrc3035
211. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 23(4):458-64. doi:10.1016/j.semcdb.2012.01.017
212. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 25(4):1425-36. doi:10.1128/MCB.25.4.1425-1436.2005
213. Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B, Bevan CL. Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors. J Biol Chem (2011) 286(20):17796-808. doi:10.1074/jbc.M110.198655
214. Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol (2006) 290(1):66-80. doi:10.1016/j.ydbio.2005.11.009
215. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem (2009) 107(5):992-1001. doi:10.1002/jcb.22199
216. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64(19):6854-7. doi:10.1158/0008-5472.CAN-04-2500
217. Danza G, Di Serio C, Ambrosio MR, Sturli N, Lonetto G, Rosati F, et al. Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int J Cancer (2013) 1(10):28293. doi:10.1002/ijc.28293
218. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res (2001) 61(19):7291-7.
219. Yong T, Sun A, Henry MD, Meyers S, Davis JN. Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J Cell Biochem (2011) 112(9):2340-51. doi:10.1002/jcb.23157
220. Wang XD, Shou J, Wong P, French DM, Gao WQ. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem (2004) 279(23):24733-44. doi:10.1074/jbc.M401602200
221. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett (2012) 3(4):879-84. doi:10.3892/ol.2012.572
222. Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol (2011) 179(1):46-54. doi:10.1016/j.ajpath.2011.03.008
223. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, et al. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res (2012) 10(2):230-8. doi:10.1158/1541-7786.MCR-11-0296
224. Orr B, Grace OC, Vanpoucke G, Ashley GR, Thomson AA. A role for notch signaling in stromal survival and differentiation during prostate development. Endocrinology (2009) 150(1):463-72. doi:10.1210/en.2008-0383
225. Wu X, Xu K, Zhang L, Deng Y, Lee P, Shapiro E, et al. Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol (2011) 356(2):337-49. doi:10.1016/j.ydbio.2011.05.659
226. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. p63 Regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol (2006) 8(6):551-61. doi:10.1038/ncb1420
227. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 20(8):1028-42. doi:10.1101/gad.1406006
228. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S, et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development (2012) 139(4):772-82. doi:10.1242/dev.071191
229. Krebs LT, Xue Y, Norton CR, Sundberg JP, Beatus P, Lendahl U, et al. Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation. Genesis (2003) 37(3):139-43. doi:10.1002/gene.10241
230. Beatus P, Lundkvist J, Oberg C, Lendahl U. The notch 3 intracellular domain represses notch 1-mediated activation through Hairy/Enhancer of split (HES) promoters. Development (1999) 126(17):3925-35.
231. Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene (2003) 22(13):1988-97. doi:10.1038/sj.onc.1206230
232. Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology (2010) 139(6):2113-23. doi:10.1053/j.gastro.2010.08.040
233. Watt FM, Estrach S, Ambler CA. Epidermal notch signalling: differentiation, cancer and adhesion. Curr Opin Cell Biol (2008) 20(2):171-9. doi:10.1016/j.ceb.2008.01.010
234. Okuyama R, Tagami H, Aiba S. Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci (2008) 49(3):187-94. doi:10.1016/j.jdermsci.2007.05.017
235. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, et al. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate (2007) 67(13):1384-96. doi:10.1002/pros.20620
236. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 103(48):18261-6. doi:10.1073/pnas.0606108103
237. Franke TF. PI3K/Akt: getting it right matters. Oncogene (2008) 27(50):6473-88. doi:10.1038/onc.2008.313
238. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 9(8):550-62. doi:10.1038/nrc2664
239. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2010) 20(1):87-90. doi:10.1016/j.gde.2009.11.002
240. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene (2006) 25(48):6416-22. doi:10.1038/sj.onc.1209888
241. Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J (2009) 418(3):475-89. doi:10.1042/BJ20082234
242. Gu T, Zhang Z, Wang J, Guo J, Shen WH, Yin Y. CREB is a novel nuclear target of PTEN phosphatase. Cancer Res (2011) 71(8):2821-5. doi:10.1158/0008-5472.CAN-10-3399
243. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 280(5369):1614-7. doi:10.1126/science.280.5369.1614
244. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci (2006) 119(Pt 24):5160-8. doi:10.1242/jcs.000133
245. Ming M, He YY. PTEN in DNA damage repair. Cancer Lett (2012) 319(2):125-9. doi:10.1016/j.canlet.2012.01.003
246. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol (2008) 28(10):3281-9. doi:10.1128/MCB.00310-08
247. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell (2003) 3(2):117-30. doi:10.1016/S1535-6108(03)00021-7
248. Zhang XP, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci U S A (2011) 108(22):8990-5. doi:10.1073/pnas.1100600108
249. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 128(1):157-70. doi:10.1016/j.cell.2006.11.042
250. Martin-Belmonte F, Gassama A, Datta A, Yu W, Rescher U, Gerke V, et al. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell (2007) 128(2):383-97. doi:10.1016/j.cell.2006.11.051
251. Tepass U. The apical polarity protein network in Drosophila epithelial cells: regulation of polarity, junctions, morphogenesis, cell growth, and survival. Annu Rev Cell Dev Biol (2012) 28:655-85. doi:10.1146/annurev-cellbio-092910-154033
252. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2012) 40(3):639-44. doi:10.3892/ijo.2011.1312
253. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 275(5308):1943-7. doi:10.1126/science.275.5308.1943
254. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15(4):356-62. doi:10.1038/ng0497-356
255. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 59(17):4291-6.
256. Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer (2007) 120(6):1284-92. doi:10.1002/ijc.22359
257. Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer (2013) 108(12):2582-9. doi:10.1038/bjc.2013.248
258. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res (2009) 29(5):1739-43.
259. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 22(8):1083-93. doi:10.1038/modpathol.2009.69
260. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature (2011) 470(7333):214-20. doi:10.1038/nature09744
261. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 487(7406):239-43. doi:10.1038/nature11125
262. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 11(4):289-301. doi:10.1038/nrc3037
263. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 304(24):2724-31. doi:10.1001/jama.2010.1877
264. Muller I, Wischnewski F, Pantel K, Schwarzenbach H. Promoter-and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications. BMC Cancer (2010) 10:297. doi:10.1186/1471-2407-10-297
265. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b ~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 3(117):2000594. doi:10.1126/scisignal.2000594
266. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 465(7301):1033-8. doi:10.1038/nature09144
267. Wu Z, He B, He J, Mao X. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate (2013) 73(6):596-604. doi:10.1002/pros.22600
268. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 100(13):7841-6. doi:10.1073/pnas.1232229100
269. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol (2012) 25(6):902-10. doi:10.1038/modpathol.2011.207
270. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol (2008) 21(12):1451-60. doi:10.1038/modpathol.2008.96
271. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 106(30):12465-70. doi:10.1073/pnas.0905931106
272. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol (2001) 21(3):893-901. doi:10.1128/MCB.21.3.893-901.2001
273. Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, et al. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol (2013) 182(3):975-91. doi:10.1016/j.ajpath.2012.11.025
274. Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann N Y Acad Sci (2013) 1280:30-4. doi:10.1111/nyas.12059
275. Watanabe H, Saito H, Ueda J, Evers BM. Regulation of pancreatic duct cell differentiation by phosphatidylinositol-3 kinase. Biochem Biophys Res Commun (2008) 370(1):33-7. doi:10.1016/j.bbrc.2008.03.012
276. Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, et al. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene (2007) 26(16):2353-64. doi:10.1038/sj.onc.1210025
277. Sayama K, Yamasaki K, Hanakawa Y, Shirakata Y, Tokumaru S, Ijuin T, et al. Phosphatidylinositol 3-kinase is a key regulator of early phase differentiation in keratinocytes. J Biol Chem (2002) 277(43):40390-6. doi:10.1074/jbc.M112423200
278. Uzan B, Figeac F, Portha B, Movassat J. Mechanisms of KGF mediated signaling in pancreatic duct cell proliferation and differentiation. PLoS One (2009) 4(3):6. doi:10.1371/journal.pone.0004734
279. Laprise P, Chailler P, Houde M, Beaulieu JF, Boucher MJ, Rivard N. Phosphatidylinositol 3-kinase controls human intestinal epithelial cell differentiation by promoting adherens junction assembly and p38 MAPK activation. J Biol Chem (2002) 277(10):8226-34. doi:10.1074/jbc.M110235200
280. Laprise P, Langlois MJ, Boucher MJ, Jobin C, Rivard N. Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells. J Cell Physiol (2004) 199(1):32-9. doi:10.1002/jcp.10432
281. Lemieux E, Boucher MJ, Mongrain S, Boudreau F, Asselin C, Rivard N. Constitutive activation of the MEK/ERK pathway inhibits intestinal epithelial cell differentiation. Am J Physiol Gastrointest Liver Physiol (2011) 301(4):7. doi:10.1152/ajpgi.00508.2010
282. Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem (2005) 280(38):32856-65. doi:10.1074/jbc.M506119200
283. Edick MJ, Tesfay L, Lamb LE, Knudsen BS, Miranti CK. Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death. Mol Biol Cell (2007) 18(7):2481-90. doi:10.1091/mbc.E06-04-0261
284. Ghosh S, Varela L, Sood A, Park BH, Lotan T. mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Res (2013) 73(16):5218-31. doi:10.1158/0008-5472.CAN-13-0429
285. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 294(5549):2186-9. doi:10.1126/science.1065518
286. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 441(7092):475-82. doi:10.1038/nature04703
287. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 441(7092):518-22. doi:10.1038/nature04747
288. Gassama-Diagne A, Yu W, ter Beest M, Martin-Belmonte F, Kierbel A, Engel J, et al. Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. Nat Cell Biol (2006) 8(9):963-70. doi:10.1038/ncb1461
289. Horne-Badovinac S, Lin D, Waldron S, Schwarz M, Mbamalu G, Pawson T, et al. Positional cloning of heart and soul reveals multiple roles for PKC? in zebrafish organogenesis. Curr Biol (2001) 11(19):1492-502. doi:10.1016/S0960-9822(01)00458-4
290. Munro EM. PAR proteins and the cytoskeleton: a marriage of equals. Curr Opin Cell Biol (2006) 18(1):86-94. doi:10.1016/j.ceb.2005.12.007
291. Yu W, Datta A, Leroy P, O'Brien LE, Mak G, Jou TS, et al. Beta1-integrin orients epithelial polarity via Rac1 and laminin. Mol Biol Cell (2005) 16(2):433-45. doi:10.1091/mbc.E04-05-0435
292. Langlois MJ, Bergeron S, Bernatchez G, Boudreau F, Saucier C, Perreault N, et al. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One (2010) 5(12):0015742. doi:10.1371/journal.pone.0015742
293. Roy SA, Langlois MJ, Carrier JC, Boudreau F, Rivard N, Perreault N. Dual regulatory role for phosphatase and tensin homolog in specification of intestinal endocrine cell subtypes. World J Gastroenterol (2012) 18(14):1579-89. doi:10.3748/wjg.v18.i14.1579
294. Vazquez de la Torre A, Junyent F, Folch J, Pelegri C, Vilaplana J, Auladell C, et al. PI3 k/akt inhibition induces apoptosis through p38 activation in neurons. Pharmacol Res (2013) 70(1):116-25. doi:10.1016/j.phrs.2013.01.007
295. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett (2006) 580(9):2294-300. doi:10.1016/j.febslet.2006.03.041
296. Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, Jia L, et al. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate (2004) 60(4):352-66. doi:10.1002/pros.20079
297. Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-Capetillo O, Nebreda AR. p38 Mitogen-activated protein kinase-and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol (2009) 29(16):4341-51. doi:10.1128/MCB.00210-09
298. Yeap BB, Wilce JA, Leedman PJ. The androgen receptor mRNA. Bioessays (2004) 26(6):672-82. doi:10.1002/bies.20051
299. Barker A, Epis MR, Porter CJ, Hopkins BR, Wilce MC, Wilce JA, et al. Sequence requirements for RNA binding by HuR and AUF1. J Biochem (2012) 151(4):423-37. doi:10.1093/jb/mvs010
300. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A (2010) 107(11):5012-7. doi:10.1073/pnas.1000896107
301. Jaworski T. Degradation and beyond: control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett (2006) 11(1):109-31. doi:10.2478/s11658-006-0011-9
302. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 18(10):2409-23. doi:10.1210/me.2004-0117
303. Dean JL, Sully G, Clark AR, Saklatvala J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal (2004) 16(10):1113-21. doi:10.1016/j.cellsig.2004.04.006
304. Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, et al. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene (2006) 25(47):6277-90. doi:10.1038/sj.onc.1209645
305. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev (2009) 23(15):1743-8. doi:10.1101/gad.1812509
306. Liu L, Rao JN, Zou T, Xiao L, Wang PY, Turner DJ, et al. Polyamines regulate c-Myc translation through Chk2-dependent HuR phosphorylation. Mol Biol Cell (2009) 20(23):4885-98. doi:10.1091/mbc.E09-07-0550
307. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem (1996) 271(14):8144-51. doi:10.1074/jbc.271.14.8144
308. Cho SJ, Jung YS, Zhang J, Chen X. The RNA-binding protein RNPC1 stabilizes the mRNA encoding the RNA-binding protein HuR and cooperates with HuR to suppress cell proliferation. J Biol Chem (2012) 287(18):14535-44. doi:10.1074/jbc.M111.326827
309. Jiang P, Smith AD, Li R, Rao JN, Liu L, Donahue JM, et al. Sphingosine kinase 1 overexpression stimulates intestinal epithelial cell proliferation through increased c-Myc translation. Am J Physiol Cell Physiol (2013) 304(12):10. doi:10.1152/ajpcell.00271.2012
310. Talwar S, Jin J, Carroll B, Liu A, Gillespie MB, Palanisamy V. Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress. J Biol Chem (2011) 286(37):32333-43. doi:10.1074/jbc.M111.255927
311. Gonsalves FC, Weisblat DA. MAPK regulation of maternal and zygotic Notch transcript stability in early development. Proc Natl Acad Sci U S A (2007) 104(2):531-6. doi:10.1073/pnas.0609851104
312. Garcia-Dominguez DJ, Morello D, Cisneros E, Kontoyiannis DL, Frade JM. Stabilization of Dll1 mRNA by Elavl1/HuR in neuroepithelial cells undergoing mitosis. Mol Biol Cell (2011) 22(8):1227-39. doi:10.1091/mbc.E10-10-0808
313. Hollenhorst PC, Paul L, Ferris MW, Graves BJ. The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer (2011) 1(10):1044-52. doi:10.1177/1947601910395578
314. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood (2013) 121(15):2964-74. doi:10.1182/blood-2012-08-446096
315. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med (2011) 208(8):1595-603. doi:10.1084/jem.20101691
316. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 13(10):1203-10. doi:10.1038/nm1636
317. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17 ~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 23(24):2806-11. doi:10.1101/gad.1872909
318. Gao M, Patel R, Ahmad I, Fleming J, Edwards J, McCracken S, et al. SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med (2012) 4(8):776-90. doi:10.1002/emmm.201100944